Aging
 Submit an Article
Online ISSN: 1945-4589
  • Home
  • Search
  • Navigate
  • Home
  • Editorial Board
  • Editorial Policies
  • Advance Publications
  • Current Issue
  • Archive
  • Special Collections
  • Scientific Integrity
  • Publication Ethics Statements
  • Interviews with Outstanding Authors
  • Newsroom
  • Sponsored Conferences
  • Contact
Rapamycin Press LLC is the publisher of Aging: www.impactjournals.com.
Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.
Impact Journals is a member of the Society for Scholarly Publishing.
Learn about our FREE Post-Publication Promotion Services
Longevity & Aging Series
Longevity and Aging
ARDD 2025
Aging Research and Drug Discovery Meeting (ARDD)
Aging Initiative at Harvard
Aging Initiative at Harvard

Search

To search the journal, enter a term in the search bar. If you'd like to find specific authors, titles, or abstracts, use the advanced search to the right.

Search Results

1 results found. Results per page: [ 20 ][ 40 ][ 60 ][ 80 ][ 100 ][ 200 ][ 300 ]

Sort by: [ Publication Date ][ Score ]

Year of publication: [ 2025 ][ 2024 ][ 2023 ][ 2022 ][ 2021 ][ 2020 ][ 2019 ][ 2018 ][ 2017 ][ 2016 ][ 2015 ][ 2014 ][ 2013 ][ 2012 ][ 2011 ][ 2010 ][ 2009 ][ Any ]

Direction: [ Desc ][ Asc ]

  • Research Paper Volume 12, Issue 21 pp 22095-22111

    Development and validation of prognostic nomogram for germ cell testicular cancer patients

    Relevance score: 15.049226
    Weipu Mao, Jianping Wu, Qingfang Kong, Jian Li, Bin Xu, Ming Chen
    Keywords: germ cell testicular cancer, prognostic nomogram, overall survival, cancer-specific survival, SEER
    Published in Aging on November 2, 2020
    Show abstract
    Hide abstract

    The purpose of our study was to establish a reliable and practical nomogram based on significant clinical factors to predict the overall survival (OS) and cancer-specific survival (CSS) of patients with germ cell testicular cancer (GCTC). Patients diagnosed with GCTC between 2004 and 2015 were obtained from the SEER database. Nomograms were constructed using the R software to predict the OS and CSS probabilities and the constructed nomograms were validated and calibrated. A total of 22,165 GCTC patients were enrolled in the study, including the training cohort (15,515 patients) and the validation cohort (6,650 patients). In the training cohort, multivariate Cox regression showed that age, race, AJCC stage, SEER stage and surgery were independent prognostic factors for OS, while age, race, AJCC stage, TM stage, SEER stage and radiotherapy were independent prognostic factors for CSS. Based on the above Cox regression results, we constructed prognostic nomograms of OS and CSS in GCTC patients and found that the OS nomograms had higher C-index and AUC compared to TNM stage in the training and validation cohorts. In addition, in the training and external validation cohorts, the calibration curves showed a good consistency between the predicted and actual 3-, 5- and 10-year OS and CSS rates of the nomogram. The current prognostic nomogram can provide a personalized risk assessment for the survival of GCTC patients.

Advanced Search

Home | Editorial Board | Editorial Policies | Advance Publications | Current Issue | Archive | Special Collections | Scientific Integrity | Publication Ethics Statements | Interviews with Outstanding Authors | Newsroom | Sponsored Conferences | Contact

By using our site you are giving us permission to use cookies. This website collects cookies to deliver a better user experience, and to analyze our website traffic and performance. Personal data is not collected. Privacy Policy | Terms Of Service

Copyright © 2025 Rapamycin Press LLC dba Impact Journals
Impact Journals ® is a registered trademark of Rapamycin Press LLC